NASDAQ: CRME TSX: COM
VANCOUVER, Sept. 17 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) today announced that Bob Rieder, Chairman and Chief Executive Officer, will present an overview of Cardiome at the ThinkEquity Partners Annual Growth Conference in San Francisco at 8:00am Pacific Time (11:00am Eastern Time) on Wednesday, September 19, 2007.
A live webcast of Mr. Rieder's presentation can be accessed on Cardiome's website at http://www.cardiome.com. A replay of the webcast will be posted after the presentation and will be available until October 19, 2007.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.
Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation (AF). Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, has completed.
Vernakalant (oral) is being investigated as a chronic-use oral drug for
the maintenance of normal heart rhythm following termination of AF.
Cardiome announced positive results from a Phase 2a pilot study for
|SOURCE Cardiome Pharma Corp.|
Copyright©2007 PR Newswire.
All rights reserved